• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Structural Heart

Boston Scientific touts Taxus Express2 trial results

May 7, 2009 By MassDevice staff Leave a Comment

Boston Scientific Corp. is touting a clinical trial comparing one of its drug-eluting stents with a bare-metal stent, published today in the New England Journal of Medicine.

Filed Under: Business/Financial News, Drug-Eluting Stents

Boston Scientific’s Tobin gets a dubious honor from Forbes

April 27, 2009 By MassDevice Leave a Comment

If you’re judged by the company you keep, James Tobin, the CEO of Natick-based stents colossus Boston Scientific Corp. might want to skip this month’s copy of Forbes.

Filed Under: Business/Financial News, Stents

Boston Scientific’s Q1 sales slip 2 percent

April 21, 2009 By MassDevice staff Leave a Comment

First-quarter sales for Boston Scientific Corp. slipped 1.8 percent to $2.01 billion, compared with $2.05 billion during the same period last year, as it struggles with a large chunk of long-term debt and fights expensive legal battles on a number of fronts.

The Natick-based devices giant plunged into the red, posting a $13 million net loss for the quarter ending March 31, compared with net income of $322 million during the first quarter of 2008.

Filed Under: Business/Financial News, Stents Tagged With: Cardiac Rhythm Management

NMT Medical’s StarFlex implant cleared for ventricular repair

April 10, 2009 By MassDevice staff Leave a Comment

NMT Medical Inc.’s StarFlex ventricular septum repair implant landed pre-market approval from the federal Food & Drug Administration.

The Boston-based company’s device is designed to be inserted into the hearts of patients with defects in the wall between the ventricular chambers.

The StarFlex implant closes the defect, preventing already-oxygenated blood from returning to the lungs before being pumped back into the body.

Filed Under: Business/Financial News, Cardiac Implants

To stent or not to stent

April 9, 2009 By MassDevice Leave a Comment

Brad Perriello

You’d think after about 20 years, questions about the efficacy of stents would be settled. You’d be wrong.

Even as players large and small scramble to get the first bioabsorbable product to market, there are conflicting reports about the best way to treat heart disease — devices or drugs?

Filed Under: Business/Financial News, Drug-Eluting Stents, Stents

NMT Medical pushes back StarFlex trial release

April 8, 2009 By MassDevice staff Leave a Comment

NMT Medical Inc. said it will release data from the clinical trial of its StarFlex implant.

Analysis of data from the study, which aims to determine whether the device can help prevent stroke or ischemia from patent formane ovale, is due to be released during the fourth quarter of 2010. PFO is a defect in the septum separating the heart’s atrial chambers.

The StarFlex implant closes the defect, preventing venous blood from returning to the body without being oxygenated by the lungs.

Filed Under: Business/Financial News, Cardiac Implants

Study: Drug-eluting stents have it over their bare cousins, at least among the AARP set

April 1, 2009 By MassDevice staff Leave a Comment

Older heart disease patients with drug-eluting stents fare better when it comes to heart attacks and mortality rates than patients with bare metal stents, according to a study funded by the federal Health & Human Services dept.’s Agency for Healthcare Research and Quality.

Filed Under: Business/Financial News, Drug-Eluting Stents, Stents

Huh? Federal courts upholds Boston Scientific’s patent claims against Johnson & Johnson — and vice versa

March 31, 2009 By MassDevice staff Leave a Comment

A federal appeals court ruled that Boston Scientific Corp. and Johnson & Johnson each infringed cardiac stent patents held by the other company, the Wall Street Journal reported.

The outcome of the 10-year court battle is still murky, despite the ruling, which failed to determine “the question of who owes what to whom,” according to the journal.

Filed Under: Business/Financial News, Drug-Eluting Stents

Abbott Labs adds another scalp to its belt in stent war with Boston Scientific

March 31, 2009 By MassDevice staff Leave a Comment

A three-year trial comparing Abbott Laboratories‘ Xience V drug-eluting stent against its Taxus competitor from Boston Scientific Corp. showed that the Abbott device is much more effective three years after implantation.

The news, announced at an American College of Cardiology conference in Orlando, sent the Natick device goliath’s stock into a slight swoon. The Xience product is already outselling the Taxus, and the news promises to accelerate that trend.

Filed Under: Business/Financial News, Drug-Eluting Stents

Boston Scientific gets another credit rating upgrade

March 25, 2009 By MassDevice staff Leave a Comment

The good news: Another credit agency raised Boston Scientific Corp.‘s rating. The bad news: The Natick-based medical devices giant is still rated as a junk bond.

Filed Under: Business/Financial News, Drug-Eluting Stents, Stents Tagged With: Cardiac Rhythm Management

Boston Scientific faces a class-action suit and settles a patent case, only to get slapped with another

March 20, 2009 By MassDevice staff

March 16 capped off a rough week for Boston Scientific Corp. and its Taxus stent line.

The Natick-based device giant found out March 14 that it faces a class-action lawsuit over the 2004 recall of its Taxus stent.

Two days later, the same day the Natick-based device giant settled a patent infringement case filed by a Texas physician, it was slapped with another by a Hong Kong cardiovascular device maker.

Filed Under: Business/Financial News, Drug-Eluting Stents

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 199
  • Go to page 200
  • Go to page 201
  • Go to page 202
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS